| Biotechnology Industry | Healthcare Sector | Mr. Jie Han CEO | XSHE Exchange | CNE1000047H6 ISIN |
| CN Country | 1,028 Employees | 6 Jul 2026 Last Dividend | 10 May 2021 Last Split | - IPO Date |
Hvsen Biotechnology Co., Ltd., established in 2002 and located in Wuhan, China, is a prominent player in the field of biotechnology. The company embarks on the research and development, as well as the manufacturing, of macrolides Active Pharmaceutical Ingredients (APIs) and preparations. Hvsen Biotechnology extends its services not only within China but also internationally, catering to a diverse range of needs in the pharmaceutical industry. The firm is well-regarded for its innovative approach towards creating veterinary drug products, including raw materials and preparations, alongside traditional Chinese medicine extractives.
Hvsen Biotechnology Co., Ltd. offers an expansive portfolio of products and services that cater to the veterinary pharmaceutical sector:
The company's commitment to innovation allows it to produce a broad assortment of veterinary drug products from raw materials to finished preparations, including the development of traditional Chinese medicines' extractives for veterinary applications. Through its extensive product range and continuous research efforts, Hvsen Biotechnology Co., Ltd. demonstrates a strong commitment to improving animal health and welfare on a global scale.